Paper · 36915750
Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1.
Huang C and 10 others. Am J Transl Res, 2023. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1. Papers, record 36915750. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36915750
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,807,225 | The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32807225 | PubMed |
| 2 | 31,743,579 | Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer. | Cancer Med | 2020 | https://conductscience.org/library/papers/31743579 | PubMed |
| 3 | 30,915,738 | MicroRNA-101-5p inhibits the growth and metastasis of cervical cancer cell by inhibiting CXCL6. | Eur Rev Med Pharmacol Sci | 2019 | https://conductscience.org/library/papers/30915738 | PubMed |
| 4 | 30,530,042 | The roles of ZEB1 in tumorigenic progression and epigenetic modifications. | Biomed Pharmacother | 2019 | https://conductscience.org/library/papers/30530042 | PubMed |
| 5 | 32,860,283 | A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration. | Cancer Sci | 2020 | https://conductscience.org/library/papers/32860283 | PubMed |
| 6 | 31,645,544 | SPRY4 is responsible for pathogenesis of adolescent idiopathic scoliosis by contributing to osteogenic differentiation and melatonin response of bone marrow-derived mesenchymal stem cells. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/31645544 | PubMed |
| 7 | 31,975,570 | Replisome genes regulation by antitumor miR-101-5p in clear cell renal cell carcinoma. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31975570 | PubMed |
| 8 | 31,943,198 | Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway. | J Cell Physiol | 2020 | https://conductscience.org/library/papers/31943198 | PubMed |
| 9 | 29,237,949 | Diagnosis and management of gastrointestinal stromal tumors: An up-to-date literature review. | J Cancer Res Ther | 2017 | https://conductscience.org/library/papers/29237949 | PubMed |
| 10 | 34,163,032 | NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay. | Oncogene | 2021 | https://conductscience.org/library/papers/34163032 | PubMed |
1 to 10 of 34
See all 34 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,653,297 | Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653297 | PubMed |
| 39,751,699 | Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway. | Hum Cell | 2025 | https://conductscience.org/library/papers/39751699 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGO2 | 27,161 | PubTator's text mining | https://conductscience.org/library/genes/27161 | NCBI Gene |
| HAUS3 | 79,441 | PubTator's text mining | https://conductscience.org/library/genes/79441 | NCBI Gene |
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| SPRY4 | 81,848 | PubTator's text mining | https://conductscience.org/library/genes/81848 | NCBI Gene |
| SPRY4-IT1 | 100,642,175 | PubTator's text mining | https://conductscience.org/library/genes/100642175 | NCBI Gene |
| ZEB1 | 6,935 | PubTator's text mining | https://conductscience.org/library/genes/6935 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36915750
GET https://conductscience.org/api/papers/v1/36915750/references?page=2